KFS
INMB icon

Kelly Financial Services’s INmune Bio INMB Stock Holding History

Kelly Financial Services’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$38.8K – 692
2021
Q3 		$38.8K Buy
+2,000
New +$38.6K 0.02% 190

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kelly Financial Services's INMB Position: Q4 2021 in Review

Kelly Financial Services sold out of INmune Bio (INMB) in Q4 2021, closing a stake of 2,000 shares — an estimated $38.8K sold.

Kelly Financial Services first reported a position in INMB in Q3 2021 and held it in 1 quarter. The position peaked at $38.8K in Q3 2021. 43 funds tracked by Wall St. Rank hold INMB as of Q4 2021.

  • Kelly Financial Services reported no remaining INmune Bio position as of Q4 2021 after selling out during the quarter.
  • Kelly Financial Services sold 2,000 INmune Bio shares in Q4 2021, an estimated $38.8K.
  • Kelly Financial Services first reported a position in INmune Bio in Q3 2021 and held it in 1 quarter.
  • Kelly Financial Services's INmune Bio position peaked at $38.8K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held INmune Bio as of Q4 2021.

Based on Kelly Financial Services's 13F filing for Q4 2021, filed 17 Jul 2024.